What is it about?
Resistance data from Clostridium perfringens BSIs enrolled during a multicentric study. Data were collected from January 2016 to December 2020. Clostridium perfringens BSIs were 134 (134/1960, 6.8 %). The highest resistance rate was observed for clindamycin (21.6 %), penicillin (15.4 %) and metronidazole (10.7 %).
Featured Image
Photo by Ahmed Al Afifi on Unsplash
Why is it important?
Clostridium perfringens reduced susceptibility phenotype to first-line therapy
Read the Original
This page is a summary of: A subanalysis of Clostridium perfringens bloodstream infections from a 5-year retrospective nationwide survey (ITANAEROBY), Anaerobe, December 2024, Elsevier,
DOI: 10.1016/j.anaerobe.2024.102901.
You can read the full text:
Contributors
The following have contributed to this page
